CLINICAL-VALUE OF A MUCIN-LIKE CARCINOMA-ASSOCIATED ANTIGEN IN MONITORING BREAST-CANCER PATIENTS IN COMPARISON WITH CA-15-3


MISEREZ A., GUNES I., MULLERBRAND J., WALTHER E., FRIDRICH R., MACKE H.

EUROPEAN JOURNAL OF CANCER, vol.27, no.2, pp.126-131, 1991 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 2
  • Publication Date: 1991
  • Doi Number: 10.1016/0277-5379(91)90468-s
  • Journal Name: EUROPEAN JOURNAL OF CANCER
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.126-131

Abstract

A new tumour marker, mucin-like carcinoma-associated antigen (MCA), was evaluated in 176 breast cancer patients classified either as free of tumour (NED, n = 141) or as having metastases (PD, n = 35). During the 5 year follow-up, 842 measurements of MCA and 363 measurements of CA 15-3 were done. MCA levels were significantly increased in the PD group (P = 0.0001) but not in the NED group. The sensitivities of the MCA and the CA 15-3 assays were 84% and 78% and the specificities were 81% and 78%, respectively. The negative predictive value of 97% for MCA was significantly higher (P = 0.0001) than the 88% for CA 15-3. Thus the MCA enzyme immunoassay is at least equivalent to the CA 15-3 test and is recommended in the assessment of metastatic spread or tumour recurrence in breast cancer patients.